Literature DB >> 34671902

Harnessing the immune system against cancer: current immunotherapy approaches and therapeutic targets.

Aswathy R Devan1, Bhagyalakshmi Nair1, Ayana R Kumar1, Balachandran S Vinod2, Lekshmi R Nath3.   

Abstract

Cancer immunotherapy is a rapidly evolving concept that has been given the tag "fifth pillar" of cancer therapy while radiation therapy, chemotherapy, surgery and targeted therapy remain the other four pillars. This involves the stimulation of the immune system to control tumor growth and it specifically targets the neoplastic cells rather than the normal cells. Conventional chemotherapy has many limitations which include drug resistance, recurrence of cancer and severe adverse effects. Immunology has made major treatment breakthroughs for several cancers such as colorectal cancer, prostate cancer, breast cancer, lung cancer, liver cancer, kidney cancer, stomach cancer, acute lymphoblastic leukaemia etc. Currently, therapeutic strategies harnessing the immune system involve Checkpoint inhibitors, Chimeric antigen receptor T cells (CAR T cells), Monoclonal antibodies, Cancer vaccines, Cytokines, Radio-immunotherapy and Oncolytic virus therapy. The molecular characterization of several tumor antigens (TA) indicates that these TA can be utilized as promising candidates in cancer immunotherapy strategies. Here in this review, we highlight and summarize the different categories of emerging cancer immunotherapies along with the immunologically recognized tumor antigens involved in the tumor microenvironment.
© 2021. The Author(s), under exclusive licence to Springer Nature B.V.

Entities:  

Keywords:  CAR T cells; CTLA-4; Cancer immunotherapy; Cancer vaccines; Checkpoint inhibitor; Cytokines; Monoclonal antibodies; Oncolytic viruses; PD-1; PD-L1

Mesh:

Substances:

Year:  2021        PMID: 34671902      PMCID: PMC8605995          DOI: 10.1007/s11033-021-06752-9

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  137 in total

Review 1.  The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.

Authors:  Katrien Vermeulen; Dirk R Van Bockstaele; Zwi N Berneman
Journal:  Cell Prolif       Date:  2003-06       Impact factor: 6.831

Review 2.  Immunological aspects of cancer chemotherapy.

Authors:  Laurence Zitvogel; Lionel Apetoh; François Ghiringhelli; Guido Kroemer
Journal:  Nat Rev Immunol       Date:  2008-01       Impact factor: 53.106

Review 3.  Adapting conventional cancer treatment for immunotherapy.

Authors:  Jian Qiao; Zhida Liu; Yang-Xin Fu
Journal:  J Mol Med (Berl)       Date:  2016-02-24       Impact factor: 4.599

Review 4.  Atypical MHC class II-expressing antigen-presenting cells: can anything replace a dendritic cell?

Authors:  Taku Kambayashi; Terri M Laufer
Journal:  Nat Rev Immunol       Date:  2014-10-17       Impact factor: 53.106

Review 5.  Harnessing innate immunity in cancer therapy.

Authors:  Olivier Demaria; Stéphanie Cornen; Marc Daëron; Yannis Morel; Ruslan Medzhitov; Eric Vivier
Journal:  Nature       Date:  2019-10-02       Impact factor: 49.962

Review 6.  Turning tumour cells into antigen presenting cells: The next step to improve cancer immunotherapy?

Authors:  Marie de Charette; Aurélien Marabelle; Roch Houot
Journal:  Eur J Cancer       Date:  2016-10-15       Impact factor: 9.162

Review 7.  Human viral oncogenesis: a cancer hallmarks analysis.

Authors:  Enrique A Mesri; Mark A Feitelson; Karl Munger
Journal:  Cell Host Microbe       Date:  2014-03-12       Impact factor: 21.023

Review 8.  Cancer and radiation therapy: current advances and future directions.

Authors:  Rajamanickam Baskar; Kuo Ann Lee; Richard Yeo; Kheng-Wei Yeoh
Journal:  Int J Med Sci       Date:  2012-02-27       Impact factor: 3.738

9.  Antigen presentation and tumor immunogenicity in cancer immunotherapy response prediction.

Authors:  Shixiang Wang; Zaoke He; Xuan Wang; Huimin Li; Xue-Song Liu
Journal:  Elife       Date:  2019-11-26       Impact factor: 8.140

Review 10.  Rationale of combination of anti-PD-1/PD-L1 antibody therapy and radiotherapy for cancer treatment.

Authors:  Hiro Sato; Noriyuki Okonogi; Takashi Nakano
Journal:  Int J Clin Oncol       Date:  2020-04-03       Impact factor: 3.402

View more
  7 in total

1.  Gene expression profiling and protein-protein interaction analysis reveals the dynamic role of MCM7 in Alzheimer's disorder and breast cancer.

Authors:  Navneeth Sriram; Sunny Mukherjee; Mahesh Kumar Sah
Journal:  3 Biotech       Date:  2022-06-10       Impact factor: 2.893

Review 2.  Aptamer-Based Cancer Cell Analysis and Treatment.

Authors:  Limei Wu; Yutong Zhang; Zhimin Wang; Yue Zhang; Jianmei Zou; Liping Qiu
Journal:  ChemistryOpen       Date:  2022-10       Impact factor: 2.630

3.  Necroptosis-Related LncRNAs Signature and Subtypes for Predicting Prognosis and Revealing the Immune Microenvironment in Breast Cancer.

Authors:  Yuhao Xu; Qinghui Zheng; Tao Zhou; Buyun Ye; Qiuran Xu; Xuli Meng
Journal:  Front Oncol       Date:  2022-05-24       Impact factor: 5.738

4.  CORR Insights®: Is Chemotherapy Associated with Improved Overall Survival in Patients with Dedifferentiated Chondrosarcoma? A SEER Database Analysis.

Authors:  Drake G LeBrun
Journal:  Clin Orthop Relat Res       Date:  2022-04-01       Impact factor: 4.755

5.  Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine.

Authors:  Sara Feola; Salvatore Russo; Beatriz Martins; Alessandra Lopes; Gaëlle Vandermeulen; Vinciane Fluhler; Camilla De Giorgi; Manlio Fusciello; Sari Pesonen; Erkko Ylösmäki; Gabriella Antignani; Jacopo Chiaro; Firas Hamdan; Michaela Feodoroff; Mikaela Grönholm; Vincenzo Cerullo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

Review 6.  Application of mRNA Technology in Cancer Therapeutics.

Authors:  Yesim Eralp
Journal:  Vaccines (Basel)       Date:  2022-08-05

Review 7.  Synthesis of glycopeptides and glycopeptide conjugates.

Authors:  Ward Doelman; Sander I van Kasteren
Journal:  Org Biomol Chem       Date:  2022-08-24       Impact factor: 3.890

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.